The IPO7 antibody is designed to target Importin-7 (IPO7), a member of the Importin β family of nuclear transport receptors. IPO7 facilitates the transport of proteins and RNA molecules between the cytoplasm and nucleus by recognizing specific cargoes, including those with nuclear localization signals (NLS). It plays a critical role in cellular processes such as gene expression regulation, signal transduction, and cell cycle progression. IPO7 is also implicated in the nuclear import of ribosomal proteins and certain viral components, highlighting its diverse functional roles.
Research on IPO7 antibodies has expanded due to their utility in studying subcellular localization, protein interactions, and nucleocytoplasmic transport mechanisms. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect IPO7 expression in various tissues and cell types. Dysregulation of IPO7 has been linked to diseases such as cancer, where altered nuclear transport may contribute to tumor progression or drug resistance. Additionally, IPO7's interaction with viral pathogens, including HIV-1. underscores its relevance in virology and host-pathogen interactions.
The development and validation of IPO7-specific antibodies have enabled deeper insights into its structural and functional dynamics, aiding both basic research and potential therapeutic targeting. Commercial antibodies are typically raised in hosts like rabbits or mice, with validated specificity for human, mouse, or rat IPO7 isoforms.